Correction to Corlanor Article
April 15 2015 - 7:52PM
Dow Jones News
The entire benefit of the 6,500-patient Corlanor study came from
a reduction in hospitalization. "FDA Approves Amgen's Heart-Failure
Drug Corlanor -- Update," at 6:10 p.m. EDT, misstated the benefits
in the fifth paragraph.
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024